On May 8, Beijing Luzhu Biotechnology Co., Ltd. (" Luzhu Biotech ", stock code: 02480.HK) was successfully listed on the main board of the Hong Kong Stock Exchange, becoming the first biotech company to be listed in Hong Kong under the Chapter 18A rule in 2023.

Since its establishment, Luzhu Biotech has focused on human vaccines and therapeutic antibody drugs, and is committed to providing human vaccines and therapeutic biologics with high quality and affordable prices. After 20 years of independent research and development and active introduction of innovative technologies, Luzhu Biotech has established a number of innovative technology platforms to enable the full cycle of drug development, laying a solid foundation for the development of candidate human vaccines, monoclonal antibody products in development and bisspecific antibody products in development.

The intermediary team of this listing is:
CICC is the sole sponsor;
Commerce & Finance Law Offices represented the company in PRC law, Eric Chow & Co. in Association with Commerce & Finance Law Offices represented the company in Hong Kong law, and O’Melveny & Myers represented the company in Hong Kong law and the United States law.
Zhong Lun Law Firm is the underwriter's lawyer in China, Wilson Sonsini Goodrich & Rosati is the underwriter's lawyer in Hong Kong and the United States;
Deloitte as auditor;
Frost & Sullivan is an industry consultant.